<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04135833</url>
  </required_header>
  <id_info>
    <org_study_id>BPI-7711DDI</org_study_id>
    <nct_id>NCT04135833</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711</brief_title>
  <official_title>A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711 in Chinese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beta Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beta Pharma, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study to assess the effect of itraconazole and rifampicin on the
      pharmacokinetic parameters of BPI-7711 in Chinese healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Blood samples collected on Day 1 and Day 20 (arm 1)/Day 25 (arm 2) at pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168 and 336 hours post BPI-7711 dose</time_frame>
    <description>Pharmacokinetics of BPI-7711 by assessment of maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-last)</measure>
    <time_frame>Blood samples collected on Day 1 and Day 20 (arm 1)/Day 25 (arm 2) at pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168 and 336 hours post BPI-7711 dose</time_frame>
    <description>Pharmacokinetics of BPI-7711 by assessment of area under the plasma concentration time curve from zero to last assessed timepoint</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Itraconazole and BPI-7711</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BPI-7711 alone followed by BPI-7711 +Itraconazole, followed by Itraconazole alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifampicin and BPI-7711</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BPI-7711 alone followed by BPI-7711 +Rifampicin, followed by Rifampicin alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPI-7711</intervention_name>
    <description>BPI-7711 60 mg</description>
    <arm_group_label>Itraconazole and BPI-7711</arm_group_label>
    <other_name>BPI-7711 capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPI-7711</intervention_name>
    <description>BPI-7711 180 mg</description>
    <arm_group_label>Rifampicin and BPI-7711</arm_group_label>
    <other_name>BPI-7711 capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Itraconazole 200 mg</description>
    <arm_group_label>Itraconazole and BPI-7711</arm_group_label>
    <other_name>Itraconazole capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>Rifampicin 600 mg</description>
    <arm_group_label>Rifampicin and BPI-7711</arm_group_label>
    <other_name>Rifampicin capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, aged from 18 to 45 years

          -  BMI from 18.5 to 28.0 kg/m2

          -  Medical history, vital signs, physical examination and lab tests are normal or
             abnormal without clinical significance

        Exclusion Criteria:

          -  Subjects with clinical significant diseases

          -  Subjects with allergic disease history

          -  Subjects with gastrointestinal disease history that can affect study drug absorption

          -  Subjects with drug abuse history
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jingying Jia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Xuhui Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Xuhui Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

